We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Recombinant Lysozyme Derived From Plants

By HospiMedica staff writers
Posted on 13 Mar 2006
A recombinant human lysozyme has been produced in an animal-free system. More...
The bacterial-cell lysis agent can be used in diagnostic applications, bioprocessing, and life science research.

The lysozyme has many advantages over other lysing agents. Because it is produced in an animal-free system, it is free of infectious viral or prion contaminants. Prions are the causative agent of bovine spongiform encephalopathy (BSE), or mad cow disease. The lysozyme outperforms chicken lysozyme, a common animal-derived cell lysis agent, and is four times more active per mg for lysing Micrococcus and E coli. Lysobac, the lysozyme produced by Ventria Bioscience (Sacramento, CA, USA), is available in packages of 100 million, 10 billion, and 100 billion.

Lysobac is a recombinant protein that provides consistent cell lysis results so that process changes are minimized. For bioprocessing applications, it saves time by eliminating steps in the production process because it enables in-culture protein extraction. In addition, Lysobac is highly active and therefore it adds minimal volume to the final extract. It is cheaper than chicken lysozyme because of its high activity and efficient production methods. Lysobac is a gentle lysing agent providing minimal risk of denaturing the protein product.



Related Links:
Ventria

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Medical Adhesive
MED 5570U
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.